Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Papuan taipan antivenom comparative trial
ACTRN12612001062819Phase 2Recruiting
- Sponsor
- University of Melbourne
- Start
- Nov 2012
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Papuan taipan envenoming (PTE) comparing ICP monovalent Papuan taipan antivenom with CSL monovalent taipan antivenom (2 arms). Primary endpoints: Prevention of airway obstruction or respiratory failure and Restoration of blood coagulability. Started Nov 2012; status: recruiting.
02
Drugs
ICP monovalent Papuan taipan antivenomCSL monovalent taipan antivenom
03
Conditions
Papuan taipan envenoming (PTE)
Beyond the preview
Go deeper on ACTRN12612001062819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001062819.